Table 1.
Demographic and clinical characteristics of patients prior to afatinib therapy.
| Characteristics | Number or Values | |
|---|---|---|
| Total number | 28 | |
| Female:Male | 13:15 | |
| Age, years | 67.4 ± 7.7 | (51–86) |
| Body weight, kg | 57.3 ± 9.4 | (35.3–78.3) |
| Body surface area, m2 | 1.59 ± 0.16 | (1.23–1.93) |
| Body mass index, kg/m2 | 22.7 ± 1.5 | (19.8–25.8) |
| Laboratory test values | ||
| White blood cell, ×103/mm3 | 5.7 ± 1.4 | (3.7–10.4) |
| Red blood cell, ×104/mm3 | 422 ± 43 | (342–498) |
| Hemoglobin, g/dL | 12.6 ± 1.7 | (8–15) |
| Platelets, ×104/mm3 | 238 ± 59 | (122–366) |
| Aspartate aminotransferase, IU/L | 22.4 ± 5.4 | (12–39) |
| Alanine aminotransferase, IU/L | 16.9 ± 5.6 | (8–30) |
| Alkaline phosphatase, IU/L | 314 ± 218 | (115–1336) |
| Lactate dehydrogenase, IU/L | 219 ± 92 | (135–601) |
| Serum albumin, g/dL | 3.8 ± 0.4 | (2.8–4.6) |
| Total bilirubin, mg/dL | 0.5 ± 0.2 | (0.3–1.1) |
| Serum creatinine, mg/dL | 0.69 ± 0.21 | (0.43–1.30) |
| eGFR, mL/min/1.73 m2 | 82.4 ± 21.4 | (43.6–125.5) |
| Stage IV:IIIb:IIb | 26:1:1 | |
| Tumor history, adenocarcinoma:other | 28:0 | |
| EGFR mutation, exon 19 deletions:exon 21 L858R:other | 16:7:5 | |
| Initial dose, 30 mg:40 mg | 7:21 | |
| Diarrhea (grade 1:2): no diarrhea | 23 (14:9):5 | |
Data are presented as number or mean ± standard deviation (range).